INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced regulatory authority approvals for Spiolto ® Respimat ® (tiotropium/olodaterol) in first ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...

The results show the benefits of tiotropium/olodaterol in improving symptoms and lung function as well as patients' satisfaction when inhaling from and handling the tiotropium/olodaterol soft-mist ...

OTEMTO ® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto ® Respimat ® right from the initial stage when patients first need maintenance therapy * Head-to-head ENERGITO ® ...

Data presented at European Respiratory Society International Congress 20181 In addition, the general condition of the patients was evaluated by the treating physician using the 8-point Physician’s ...

Boehringer Ingelheim has secured first European approvals for its new once-daily treatment for chronic obstructive pulmonary disease, Spiolto Respimat. The drug combines the long-acting muscarinic ...

Boehringer Ingelheim, a leading pharmaceutical company, announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European ...

Respimat from Boehringer Ingelheim is now the first and only inhaler to be awarded the Ease of Use Commendation by the Arthritis Foundation. This award identifies products that make life easier for ...

Boehringer Ingelheim announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat ...

Pharmacists are likely to see people with COPD and asthma more regularly than a GP or nurse, so they play a pivotal role in educating patients on their medicines and inhaler technique. Boehringer ...

The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its ...

OTEMTO trials show Spiolto Respimat provides clinically meaningful >4 point reduction in SGRQ score compared to placebo i The results underline the benefit Spiolto Respimat can bring to the daily life ...